DFM Platform

Capability

DNA Script: Enzymatic DNA Synthesis and European Biological Sovereignty

How does DNA Script's enzymatic DNA synthesis and the SYNTAX benchtop DNA printer enable rapid on-site production of custom oligonucleotides?

DNA Script SAS is a Paris-based deep-tech biotechnology company specializing in enzymatic DNA. Defence-finance analysis; 14-page sourced DFM PDF report.

Full figures, sources and the complete assessment are in the report — Read the full DFM Analysis →

Part of our Research, Universities & Deep Tech and Defence & Dual-Use Companies coverage →

Original DFM publication · DFM Analysis report · 2025-12-28

DNA Script SAS is a Paris-based deep-tech biotechnology company specializing in enzymatic DNA synthesis . Founded in 2014, it has developed the SYNTAX® platform, the world’s first benchtop DNA “printer,” enabling rapid on-site production of custom oligonucleotides for research and diagnostics.

Headquartered in Le Kremlin-Bicêtre (Paris metropolitan area) , DNA Script maintains additional operations in the United States (South San Francisco, California ) and a global distribution network (e.g. Middle East distributor in Dubai ). Its official website is dnascript.com (with active social media channels for press and support).

This analysis answers: How does DNA Script's enzymatic DNA synthesis and the SYNTAX benchtop DNA printer enable rapid on-site production of custom oligonucleotides? What is the readiness of DNA Script's platform and its relevance to European biological sovereignty and dual-use biodefence? What is DNA Script's footprint (France HQ, US operations, global distribution network) and its partnerships and market strategy? What capability gaps, IP assets and strategic indicators shape DNA Script's contribution to European biotech autonomy?

Key takeaways

  • Middle East distributor in Dubai ).
  • Its official website is dnascript.com (with active social media channels for press and support).

Continue with the full evidence

This public thread is the short analytical version. The full DFM Analysis report adds the underlying figures and data, the complete source base, and the full procurement & capital-market assessment behind this summary.

Need the full document as a standalone file? Buy the full report (PDF) — €299

Annual Professional unlocks the complete archive and DFM Intelligence (2,200+ company profiles) — See plans →

Original DFM analysis

DNA Script: Enzymatic DNA Synthesis and European Biological Sovereignty

Type DFM Analysis report
Published 2025-12-28
Access free_public

FAQ

What is DNA Script: Enzymatic DNA Synthesis and European Biological Sovereignty?

Founded in 2014, it has developed the SYNTAX® platform, the world’s first benchtop DNA “printer,” enabling rapid on-site production of custom oligonucleotides for research and diagnostics.

Why does DNA Script: Enzymatic DNA Synthesis and European Biological Sovereignty matter for European defence?

Headquartered in Le Kremlin-Bicêtre (Paris metropolitan area) , DNA Script maintains additional operations in the United States (South San Francisco, California ) and a global distribution network (e.g.

Professional comments

Join the discussion on DFM Analysis.

Read & subscribe on DFM Analysis →

Related DFM Platform threads

Explore this category Strategic Autonomy

Explore related themes Dual-Use Tech Transfer

Professional requests (internal interest signal — not a marketplace; nothing is charged or promised)

Defence Finance Monitor is an analytical and informational product. It does not constitute investment advice, financial advice or a recommendation to buy or sell securities. Subscriptions run on DFM Analysis. Payments for Professional Packs are processed securely by Stripe at checkout.